145 related articles for article (PubMed ID: 37345534)
1. ELF3 suppresses gallbladder cancer development through downregulation of the EREG/EGFR/mTOR complex 1 signalling pathway.
Nakamura T; Nishikawa Y; Shiokawa M; Takeda H; Yokode M; Matsumoto S; Muramoto Y; Ota S; Yoshida H; Okada H; Kuwada T; Marui S; Matsumori T; Maruno T; Uza N; Kodama Y; Hatano E; Seno H
J Pathol; 2023 Sep; 261(1):28-42. PubMed ID: 37345534
[TBL] [Abstract][Full Text] [Related]
2. ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer.
Yang L; Wang H; Guo M; He M; Zhang W; Zhan M; Liu Y
Cell Oncol (Dordr); 2023 Aug; 46(4):1085-1095. PubMed ID: 36988891
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition.
Zong H; Yin B; Zhou H; Cai D; Ma B; Xiang Y
Mol Biol Rep; 2014 Jul; 41(7):4507-12. PubMed ID: 24623408
[TBL] [Abstract][Full Text] [Related]
5. EREG-driven oncogenesis of Head and Neck Squamous Cell Carcinoma exhibits higher sensitivity to Erlotinib therapy.
Liu S; Wang Y; Han Y; Xia W; Zhang L; Xu S; Ju H; Zhang X; Ren G; Liu L; Ye W; Zhang Z; Hu J
Theranostics; 2020; 10(23):10589-10605. PubMed ID: 32929368
[No Abstract] [Full Text] [Related]
6. PLEK2 promotes gallbladder cancer invasion and metastasis through EGFR/CCL2 pathway.
Shen H; He M; Lin R; Zhan M; Xu S; Huang X; Xu C; Chen W; Yao Y; Mohan M; Wang J
J Exp Clin Cancer Res; 2019 Jun; 38(1):247. PubMed ID: 31182136
[TBL] [Abstract][Full Text] [Related]
7. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
[TBL] [Abstract][Full Text] [Related]
8. The Role of EREG/EGFR Pathway in Tumor Progression.
Cheng WL; Feng PH; Lee KY; Chen KY; Sun WL; Van Hiep N; Luo CS; Wu SM
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884633
[TBL] [Abstract][Full Text] [Related]
9. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate.
Pandey A; Stawiski EW; Durinck S; Gowda H; Goldstein LD; Barbhuiya MA; Schröder MS; Sreenivasamurthy SK; Kim SW; Phalke S; Suryamohan K; Lee K; Chakraborty P; Kode V; Shi X; Chatterjee A; Datta K; Khan AA; Subbannayya T; Wang J; Chaudhuri S; Gupta S; Shrivastav BR; Jaiswal BS; Poojary SS; Bhunia S; Garcia P; Bizama C; Rosa L; Kwon W; Kim H; Han Y; Yadav TD; Ramprasad VL; Chaudhuri A; Modrusan Z; Roa JC; Tiwari PK; Jang JY; Seshagiri S
Nat Commun; 2020 Aug; 11(1):4225. PubMed ID: 32839463
[TBL] [Abstract][Full Text] [Related]
10. miR-4461 inhibits the progression of Gallbladder carcinoma via regulating EGFR/AKT signaling.
Yan X; Yang P; Liu H; Zhao Y; Wu Z; Zhang B
Cell Cycle; 2022 Jun; 21(11):1166-1177. PubMed ID: 35196196
[TBL] [Abstract][Full Text] [Related]
11. Loss of NDRG2 promotes epithelial-mesenchymal transition of gallbladder carcinoma cells through MMP-19-mediated Slug expression.
Lee DG; Lee SH; Kim JS; Park J; Cho YL; Kim KS; Jo DY; Song IC; Kim N; Yun HJ; Park YJ; Lee SJ; Lee HG; Bae KH; Lee SC; Shim S; Kim YM; Kwon YG; Kim JM; Lee HJ; Min JK
J Hepatol; 2015 Dec; 63(6):1429-39. PubMed ID: 26292259
[TBL] [Abstract][Full Text] [Related]
12. Autocrine epiregulin activates EGFR pathway for lung metastasis via EMT in salivary adenoid cystic carcinoma.
Liu S; Ye D; Xu D; Liao Y; Zhang L; Liu L; Yu W; Wang Y; He Y; Hu J; Guo W; Wang T; Sun B; Song H; Yin H; Liu J; Wu Y; Zhu H; Zhou BP; Deng J; Zhang Z
Oncotarget; 2016 May; 7(18):25251-63. PubMed ID: 26958807
[TBL] [Abstract][Full Text] [Related]
13. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha promotes gallbladder cancer proliferation and metastasis through activating phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway.
Lyu WJ; Shu YJ; Liu YB; Dong P
Chin Med J (Engl); 2020 Oct; 133(19):2321-2329. PubMed ID: 32925281
[TBL] [Abstract][Full Text] [Related]
15. Epiregulin reprograms cancer-associated fibroblasts and facilitates oral squamous cell carcinoma invasion via JAK2-STAT3 pathway.
Wang Y; Jing Y; Ding L; Zhang X; Song Y; Chen S; Zhao X; Huang X; Pu Y; Wang Z; Ni Y; Hu Q
J Exp Clin Cancer Res; 2019 Jun; 38(1):274. PubMed ID: 31234944
[TBL] [Abstract][Full Text] [Related]
16. Estrogen-related receptor-α promotes gallbladder cancer development by enhancing the transcription of Nectin-4.
Wang L; Yang M; Guo X; Yang Z; Liu S; Ji Y; Jin H
Cancer Sci; 2020 May; 111(5):1514-1527. PubMed ID: 32030850
[TBL] [Abstract][Full Text] [Related]
17. ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί.
Lee JS; Choi YE; Kim S; Han JY; Goh SH
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830169
[TBL] [Abstract][Full Text] [Related]
18. E74-Like Factor 3 Is a Key Regulator of Epithelial Integrity and Immune Response Genes in Biliary Tract Cancer.
Suzuki M; Saito-Adachi M; Arai Y; Fujiwara Y; Takai E; Shibata S; Seki M; Rokutan H; Maeda D; Horie M; Suzuki Y; Shibata T; Kiyono T; Yachida S
Cancer Res; 2021 Jan; 81(2):489-500. PubMed ID: 33293429
[TBL] [Abstract][Full Text] [Related]
19. The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer.
Zhang M; Gong W; Zuo B; Chu B; Tang Z; Zhang Y; Yang Y; Zhou D; Weng M; Qin Y; Ma M; Jiang A; Ma F; Quan Z
Oncotarget; 2016 Nov; 7(48):78640-78652. PubMed ID: 27769047
[TBL] [Abstract][Full Text] [Related]
20. E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma.
Gondkar K; Patel K; Krishnappa S; Patil A; Nair B; Sundaram GM; Zea TT; Kumar P
Cancer Biomark; 2019; 25(2):223-232. PubMed ID: 31104013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
